Inhibition of RAB7 promotes CD8

Xiaoli Liu, Zhiqiang Jiang, Ruijie Li, Jia Li, Lu Zhang, Huaimin Liu

Abstract read

In one paragraph

Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaoli LiuDepartment of Integrated Traditional Chinese and Western Medicine, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital Zhengzhou 450008, Henan, China.

Zhiqiang JiangDepartment of General Surgery, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital Zhengzhou 450008, Henan, China.

Ruijie LiDepartment of Medical Oncology, Henan Provincial Chest Hospital Zhengzhou 450000, Henan, China.

Jia LiDepartment of Integrated Traditional Chinese and Western Medicine, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital Zhengzhou 450008, Henan, China.

Lu ZhangDepartment of Integrated Traditional Chinese and Western Medicine, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital Zhengzhou 450008, Henan, China.

Huaimin LiuDepartment of Integrated Traditional Chinese and Western Medicine, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital Zhengzhou 450008, Henan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Programmed cell death protein 1 (PD-1) antibody is facing the challenge of drug resistance in cancer therapy. RAB7 plays a key role in autophagic lysosomal fusion, but its function in tumor immune regulation, especially whether it can enhance the efficacy of PD-1 inhibitors, is not clear. RAS-associated binding protein 7 (RAB7) and stimulator of interferon gene (STING) were knocked down by siRNA in lung squamous cell carcinoma (LUSC) cells. The effects of RAB7 and STING on the malignant phenotype of cells were evaluated. The autophagy flux and cytoplasmic double-stranded DNA (dsDNA) accumulation were observed by Western blot, RFP-GFP-LC3B tandem fluorescent probe, transmission electron microscopy and immunofluorescence. The expression of STING/interferon regulatory factor 1 (IRF1) pathway was analyzed by Western blot. CD8

Indexed as

CD8+ T cellslung cancerprogrammed cell death protein 1RAS-associated binding protein 7

Identifiers

PMID41868680

DOI10.62347/KRNB3973

PMCPMC13000129

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.